Patrick Loustau

Patrick Loustau

3rd Annual Gross-to-Net Accounting & Accruals | Healthcare Finance News

Bristol-Myers Squibb - Led by Distinguished Chairman David Levi of Bristol-Myers Squibb, Don’t miss the industry event that convenes over 200 GTN Accounting and Finance executives each year! Pharmaceutical manufacturers are tasked with a huge volume of transactions and contracts. These are complex, often ...

David Levi, CPA

Mentioned in this article:
David Levi, CPA

Bristol Myers Squibb Company Submits NDAs For

Bristol-Myers Squibb - "These FDA submissions represent a major step towards offering daclatasvir-based regimens to U.S. HCV patients, many of whom continue to have high unmet medical needs," said Brian Daniels, MD, senior vice president, Global Development and Medical Affairs, Research and Development...

Brian Daniels

Mentioned in this article:
Brian Daniels

George Zavoico: Biotech Stocks That Deserve A Closer Look - Seeking Alpha

Bristol-Myers Squibb - In this Life Sciences Report interview, Senior Analyst and Managing Director George Zavoico of MLV & Co. identifies a group of biotech companies with market-moving events on their calendars. Sharpen your pencils: From cancer to coronary artery disease to vaccine technology...

George Zavoico

Mentioned in this article:
George Zavoico

FDA Approves Pfizer And BMS’ sNDA For Eliquis

Bristol-Myers Squibb - Brian Daniels, Senior Vice President of global development and medical affairs at Bristol-Myers Squibb, said “Today’s FDA approval of Eliquis for DVT prophylaxis in patients who have undergone hip or knee replacement is a significant milestone for this important medicine, which is also ...

Brian Daniels

Mentioned in this article:
Brian Daniels

Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Cowen and Company 34th...

Brian Daniels, senior vice president, Global Development and Medical Affairs, will make a formal presentation about the company at 10 a.m. Bristol-Myers Squibb Company (BMY), currently valued at $88.86B, began trading this morning at $53.63. Looking at the equity, the company’s one day ...

Pharmaceutical giant settles on new Tampa office location | Bay News 9

Bristol-Myers Squibb - "We designed our facility with an eye toward building a dynamic culture...and help us maintain our position as a global biopharma leader," said Gareth Morgan, senior vice president, Bristol-Myers Squibb. "At our Tampa facility, we will build a culture of innovation and continuous ...

Gareth Morgan

Mentioned in this article:
Gareth Morgan

peHUB | Private equity and venture capital news, data and community

Bristol-Myers Squibb - And, Dr. Peter Kiener, will serve as a business and scientific advisor to Sialix. Headquartered in Cambridge, Mass., Sialix is a developer of products that treat cancer and chronic inflammatory conditions. Cambridge, Massachusetts, July 30, 2013 –Sialix, Inc., a company developing ...

Peter Kiener

Mentioned in this article:
Peter Kiener

Stephen Sadove to join JCPenney board of directors | Positions and Promotions

Bristol-Myers Squibb - October 10, 2013, Plano, Tx., USA - J. C. Penney Company, Inc. announced that Stephen I. Sadove has been elected to its board of directors. Mr. Sadove is currently chairman and chief executive officer of Saks Incorporated and will be leaving Saks upon completion of its previously ...

Stephen Sadove

Mentioned in this article:
Stephen Sadove

Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results -- SAN DIEGO, M...

Bristol-Myers Squibb - Ted Schroeder, President and CEO of Cadence, stated, "Our fourth quarter 2012 revenue exceeded our guidance as we ended the year with strong sales growth and momentum. We continue to expand our customer base and drive higher OFIRMEV utilization rates as physicians increasingly recognize ...

Ted Schroeder

Mentioned in this article:
Ted Schroeder

CEO of drug maker Teva out ahead job cuts | Yahoo Health

Bristol-Myers Squibb - In a statement, Teva said its board of directors and President and CEO Jeremy Levin had agreed for him to step down. It gave no reason for the resignation, but the shakeup exposed cracks in the leadership of the world's largest generic drug maker. The company's statement was quickly ...

Dr. Jeremy M. Levin

Mentioned in this article:
Dr. Jeremy M. Levin

Join Newsle to find out when Patrick Loustau makes the news.

As a Newsle member, you’ll be able to:

  • Get alerts on Patrick Loustau
  • See news articles & blog posts about Patrick Loustau
  • Follow your friends & colleagues in the news
This profile only includes publicly available information. Questions or comments? Contact Us
Freebase CC-BY
Data from Freebase, licensed under CC-BY
Source: CrunchBase
Data from Wikipedia, licensed under the GFDL